Welcome to our dedicated page for Avenue Therapeutics news (Ticker: ATXI), a resource for investors and traders seeking the latest updates and insights on Avenue Therapeutics stock.
Avenue Therapeutics Inc (ATXI) is a specialty pharmaceutical company advancing therapies for acute pain management and neurological disorders. This page provides timely updates on clinical developments, regulatory milestones, and corporate announcements essential for tracking the company’s progress.
Investors and industry observers will find a centralized repository of press releases, earnings reports, and strategic partnership updates. Key focus areas include IV Tramadol for postoperative pain, AJ201 targeting spinal and bulbar muscular atrophy, and BAER-101 for epilepsy and panic disorders.
Content spans clinical trial results, FDA communications, financial performance summaries, and research collaborations. Bookmark this page for streamlined access to verified ATXI updates, ensuring informed decision-making without promotional bias.
Avenue Therapeutics, Inc. (Nasdaq: ATXI), a specialty pharmaceutical company focused on neurologic diseases, will present a corporate update at the Aegis Capital Virtual Conference on May 4, 2023, at 4:00 p.m. EDT. CEO Alexandra MacLean will lead the presentation. Interested participants can access the zoom link on Avenue's website for 30 days post-event. Avenue is developing three key assets: AJ201 for spinal and bulbar muscular atrophy, BAER-101 for CNS diseases, and IV Tramadol, currently in Phase 3 clinical development for pain management. Founded by Fortress Biotech, Avenue Therapeutics is headquartered in Miami, FL.
Avenue Therapeutics, Inc. (Nasdaq: ATXI) has received official meeting minutes from the FDA following a Type C meeting on March 9, 2023, regarding the development of IV Tramadol for post-operative pain management. The FDA agreed on most aspects of the proposed study protocol, addressing the risk of opioid-induced respiratory depression compared to IV morphine. This follows earlier discussions in August 2022, where the FDA found the proposed study design reasonable. Avenue aims to finalize the protocol based on FDA feedback, with plans to initiate a Phase 3 safety study in 2023. A successful trial outcome could pave the way for IV Tramadol's approval. Avenue also plans to update on its additional programs targeting spinal muscular atrophy and epilepsy later this year.
FAQ
What is the current stock price of Avenue Therapeutics (ATXI)?
What is the market cap of Avenue Therapeutics (ATXI)?
